Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tibotec Pharmaceuticals has returned the licensing rights for a treatment for hepatitis B to Medivir.
Subscribe to our email newsletter
In previous pre-clinical trials, MIV-210 has demonstrated very potent activity against hepatitis B virus (HBV) and has good pharmacokinetic properties, according to the companies.
MIV-210 belongs to the class of polymerase inhibitors being administered by subsidiary Medivir HIV franchise AB.